biostudies-literatureUnknown11(1)Ding JThe prognosis of most thyroid cancer patients is excellent, but for those with advanced or metastatic thyroid cancer, effective treatments are still lacking. Chimeric antigen receptor (CAR) T-cell therapy has gained remarkable achievements in hematologic malignancy but shown limited efficacy in solid tumors. In this report, we showed a relapsed and refractory thyroid cancer patient treated with TSHR + CD19 CAR-T, a combination of two 2nd generation CAR-T molecules targeting both TSHR and CD19. This patient finally achieved partial remission at 3 months and was tolerate well to the regimen. Our study suggested that the CAR-T therapy could be a feasible way in treating relapsed and refractory thyroid cancer.Experimental hematology & oncology59https://www.ebi.ac.uk/biostudies/studies/S-EPMC9494903biostudies-literatureChimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer.PMC9494903Liu XHei HLi DSun BZhou DDing JZhou KSong YfalseChimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer.The prognosis of most thyroid cancer patients is excellent, but for those with advanced or metastatic thyroid cancer, effective treatments are still lacking. Chimeric antigen receptor (CAR) T-cell therapy has gained remarkable achievements in hematologic malignancy but shown limited efficacy in solid tumors. In this report, we showed a relapsed and refractory thyroid cancer patient treated with TSHR + CD19 CAR-T, a combination of two 2nd generation CAR-T molecules targeting both TSHR and CD19. This patient finally achieved partial remission at 3 months and was tolerate well to the regimen. Our study suggested that the CAR-T therapy could be a feasible way in treating relapsed and refractory thyroid cancer.2022-01-01T00:00:00Z2022 Sep2025-04-26T12:00:05.613Z2025-04-06T13:49:47.239ZS-EPMC94949033613844410.1186/s40164-022-00311-z